

- ⁷ 23 Division of Medical Microbiology and Virology, St. Paul's Hospital, Vancouver, British
- 24 Columbia, Canada
- ⁸ 25 Ministry of Health, Victoria, British Columbia, Canada
- 26

27 *Corresponding author

- 28 **Address for correspondence:**
- 29 Catherine A. Hogan
- 30 655 W 12th Avenue, Room 2054
- 31 Vancouver, BC, Canada, V6R 2M7
- 32 Phone (604) 802-5183
- 33 catherine.hogan@bccdc.ca

34 **Abstract (**169 words**)**

55 *Introduction*

56 SARS-CoV-2 viral burden can be quantitated by the use of polymerase chain reaction (PCR) 57 cycle threshold (Ct) values, which are inversely proportional to the amount of target viral 58 sequence present in the patient sample. Although this information is frequently available from 59 routine molecular methods for the diagnosis of SARS-CoV-2 infection, clinical results are 60 almost universally reported qualitatively as present or absent due to sources of sampling 61 variability, lack of inter-test standardization, insufficient supporting clinical correlation data, and 62 lack of regulatory approval for purposes other than qualitative reporting, all of which limit 63 interpretation of Ct values for clinical care. Though the use of Ct values to guide individual-level 64 management is not currently routinely recommended $(1, 2)$, the assessment of aggregated Ct 65 values at a population level may be useful to help assess early epidemiological transmission 66 trends to improve epidemic forecasting (3-5), and parallels the concept of measuring community 67 viral load used for other viruses (6-8). Accurate projection of epidemic trends is critical to 68 effectively plan public health efforts including healthcare resource allocation. Indeed, an 69 epidemic in the growth phase is more likely to be associated with high viral load burden at a 70 population level; conversely, the decline phase of an epidemic is likely to demonstrate lower 71 viral burden. A modeling approach was previously published to inform epidemic SARS-CoV-2 72 trajectory based on aggregated Ct value data (3), and supported the usefulness of population-73 level Ct value analysis. However, SARS-CoV-2 testing practices globally have evolved 74 substantially during the pandemic, most frequently by restricting testing to symptomatic 75 individuals, which limits the usefulness of modeling approaches that rely on stable population 76 sampling strategies. Starting in December 2021 in British Columbia (BC), use of PCR testing 77 was partially restricted in the context of roll-out of rapid antigen tests, limiting understanding of

78 population trends. New tools are needed to estimate incidence in a manner that is independent of 79 the biases associated with testing guidance. This includes modeling approaches robust to varying 80 testing guidelines, sample selection strategies and epidemiologic settings, and that account for 81 other variables that impact viral burden such as variant of concern (VoC) and vaccination status. 82 The main variants of concern (VoC) described to date have been associated with varying impact 83 on viral burden, with the Delta and certain Omicron subvariants associated with highest viral 84 load (9-14). Furthermore, evidence suggests that SARS-CoV-2 vaccination is associated with a 85 reduction in viral burden, and correspondingly higher Ct values and potentially lower 86 transmission risk, in individuals who develop post-vaccination infection (14-19). In this study, 87 we investigated two modeling approaches based on Ct value distribution of asymptomatic 88 individuals, machine learning and epidemic transmission modeling, to predict SARS-CoV-2 89 incidence based on province-wide data and an outbreak in a long-term care facility in British 90 Columbia, Canada. We assessed the novel application of five machine learning models (Lasso, 91 LGBM, XGBoost, CatBoost, RF), and validated two previously-described epidemic models 92 (SEIR) (3), to determine the highest performing models across a range of epidemiological 93 settings to predict SARS-CoV-2 incidence.

94

95 *Methods*

96 **Study design**

97 Individuals with polymerase chain reaction (PCR)-confirmed SARS-CoV-2 infection by 98 nasopharyngeal swab or saline gargle between November $19th 2021$ and January 8th 2022 were 99 included, capturing emergence of Omicron wave in the province. Descriptive analyses of Ct 100 value distribution included the two main specimen type categories: nasopharyngeal swabs and

123 2) targeted testing (starting March 16, 2020), 3) expanded testing (starting April 9, 2020), 4)

132

133 **Laboratory data - SARS-CoV-2 diagnostic testing**

134 SARS-CoV-2 diagnostic testing was performed in laboratories throughout all five health

135 authorities in BC, and only assays based on the *E* gene target were included for this study. The

136 testing strategy and test result interpretation criteria used for the participating laboratories are

137 described separately (**Supplemental Table 2**), and included the BCCDC PHL laboratory-

138 developed test (LDT) (22), LightMix SarbecoV E-gene plus EAV control assay (TIB Molbiol,

139 Berlin, Germany), Alinity m SARS-CoV-2 (Abbott, Chicago, IL), BD SARS-CoV-2 (Becton,

- 140 Dickinson and Co., Franklin Lakes, NJ), cobas 6800 and 8800 (Roche Diagnostics, Basel
- 141 Switzerland), GeneXpert Xpress SARS-CoV-2 (Cepheid, Sunnyvale, CA), Panther Fusion
- 142 (Hologic, San Diego, CA) and Allplex SARS-CoV-2 (Seegene, Seoul, South Korea). For
- 143 individuals having undergone repeat SARS-CoV-2 testing within a one-week period, only the
- 144 first positive test per person was included.
- 145

146 **Laboratory data - Variant of Concern identification**

147 The BCCDC Public Health Laboratory (PHL) continuously monitors for variants of concern 148 (VOCs), variants of interest (VOIs), and variants under monitoring (VUMs). Various approaches 149 were used over time including VoC screening and confirmation by whole genome sequencing 150 (WGS) when applicable at the BCCDC PHL as previously described (22). Testing strategy is 151 optimized based on available capacity and clinical and public health needs, and changed over the 152 course of the SARS-CoV-2 pandemic. One such strategy included deployment of in brief, a 153 subset of samples in the earlier phase of the epidemic (January 2021 to May 2021) was tested by 154 targeted single nucleotide polymorphism (SNP) quantitative polymerase chain reaction (qPCR) 155 for VoC screening, followed by confirmation by WGS. From June 2021 onward, sample VoC 156 status was detected by WGS alone. From September 2021, owing to increased case burden and 157 limited capacity, there was a transition from WGS of all samples to a subset positive SARS-158 CoV-2 samples. This subset comprised of targeted surveillance (cases from outbreaks, vaccine 159 escape, reinfection and travel-related), and representative baseline surveillance. In addition, 160 100% of positive samples underwent WGS in the first week of each month. Starting November 161 15 2021 in the context of the Omicron variant emergence, WGS was resumed for all samples. 162 Owing to the high transmissibility of Omicron and the surge in case load, starting December 21 163 2021, there was transition from full sequencing to sequencing a subset of representative positive 164 samples in addition to priority cases (including outbreaks, long-term care, vaccine escape, travel-165 related, hospitalization)). Full VoC characterization for the province of BC is described 166 separately (**Supplemental Figure 2**).

167

168 **Vaccination status**

169 Vaccination status was defined based on the date of vaccine receipt relative to the date of the 170 sample collection included for the study (**Supplemental Figure 3**) (23). For primary dose series 171 all mRNA (Pfizer, Moderna) and viral vector vaccines (AstraZeneca, Janssen) were considered. 172 For the Janssen vaccine only, fully vaccinated status was defined as having received one dose 14 173 days or more prior to sample collection. For all other vaccines, **Unvaccinated status** was defined 174 as having received no SARS-CoV-2 vaccine, or having received a SARS-CoV-2 vaccine less 175 than 21 days prior to the sample collection date. **Partially vaccinated** status was defined as 176 having received the SARS-CoV-2 vaccine dose 1 greater or equal to 21 days prior to sample 177 collection, but having received dose 2 less than 14 days prior to the sample collection. **Fully** 178 **vaccinated** status was defined as greater or equal to 14 days since the receipt of dose 2, but 179 having received dose 3 less than 14 days prior to the sample collection. Cross-over vaccination 180 was considered in the same category as homologous vaccine schedules.

181

182 **Outbreak case study**

183 To further validate the models, a separate analysis was performed using a well-characterized 184 outbreak in a long-term care facility that occurred in BC. This outbreak was selected on the 185 basis of time of occurrence of pre-vaccination roll-out to the general population, large size and 186 generalizability of the affected population. This outbreak included large-scale asymptomatic 187 testing. Testing was done weekly until no additional cases were identified within 14 days of the 188 last exposure. There were 7 rounds of weekly testing at the outbreak facility, all negative 189 residents and staff were tested for each round. Anyone who developed symptoms was also tested. 190 The epidemiologic data and curve describing the outbreak are presented separately 191 (**Supplemental Figure 4**). As for the main study, analysis was based on SARS-CoV-2

192 diagnostic tests based on the *E* gene target. However, due to missing data in the long-term care 193 facility data, wherever the *E* gene target was unavailable the *ORF1* gene target was used instead. 194

195 **Data sources**

196 Two main data sources were employed for this study: 1) the Provincial Health Laboratory

197 Viewer and Reporter (PLOVER) database which includes the laboratory diagnostic datasets, and

198 2) the Provincial Immunization Registry (PIR) dataset which includes vaccination data. The

199 laboratory datasets house data on SARS-CoV-2 testing (including date of collection, specimen

200 type, diagnostic quantitative PCR gene target results, VoC screening, and SARS-CoV-2 lineage

201 based on WGS), and individual-level epidemiological data (including age, sex, patient as well as 202 ordering physician health authority). Gene target results include Ct values of the *E* and ORF1

203 targets, and the internal control RNAseP. The PIR dataset includes individual-level vaccination

204 data (including number, type, series, dose and date of each vaccine received). Both of these

205 datasets form the basis of the covariates which inform the ML models in the study. For the

206 outbreak case study, additional data were directly gathered from public health partners

207 (**Supplemental Figure 4**) as these were not otherwise available through provincial datasets. Data

208 linkages were performed between the laboratory and PIR datasets through a sequential

209 deterministic linkage based on a minimum of three personal identifiers (personal health number,

210 last name with first three digits of first name, and date of birth). These linkages were performed

211 prospectively on a weekly basis, and specimens with unsuccessful linkages were excluded from

212 the study.

213

214 **Data & Code Availability**

239 kurtosis. The trained data was generated from a unique simulation file with a fixed random seed 240 and three distinct sample sizes, so three models were investigated in this study. Hyperparameter 241 tuning was performed via a grid search of hyperparameters on each model (**Supplemental Table** 242 **5**). The best performing model was chosen by finding the optimal set of hyperparameters for 243 which the Mean squared error (MSE) between the true simulated Rt and Predicted simulated Rt 244 was minimized. SHapley Additive exPlanation (SHAP) analysis was performed for feature 245 ranking and importance (25). The second modeling approach was adapted from an existing 246 methodology (3), and is based on a single epidemic model. The compartmental SEIR model 247 captures different stages in individual infections (namely **S**usceptible, **E**xposed, **I**nfectious and 248 **R**ecovered). The SEIR model was validated on a patient outbreak facility in BC where point 249 prevalence testing was done in infrequent intervals. The SEIR model was then fitted to 250 provincial data from asymptomatic individuals. Modifications to the viral kinetics for the SEIR 251 model were applied to these provincial data to account for the specific nature of the Omicron 252 (BA.1) variant.

253

254 *Results*

255 Cohort description

256 During the study period, a total of 331,785 SARS-CoV-2 tests were performed in BC, of which

257 79,443 were positive. Restricting these to the first positive test per person, there were 71,642

258 included in the study (**Figures 1A and 1B**). Of these, 35,369 were nasopharyngeal specimens

259 and 36,108 were saline gargle specimens (**Table 1 and Figure 2**). The cohort was predominantly

260 composed of adults aged 18-59 years (72.2%), followed by adults aged 60 years and above

261 (12.1%), and children 0-17 years (15.7%). Over half the cases resided in two of the five health

262 authorities accounting for 35.9% and 30.9%, respectively. The Omicron (BA.1) variant

- 263 predominated throughout the study (**Table 1 and Supplemental Figure 2**). By the end of the
- 264 study period, a total of 18,459 (27.3%) were unvaccinated, 1,540 (2.3%) had received 1 dose of
- 265 vaccine, and 47,580 (70%) were fully vaccinated.
- 266

267 **First modeling approach: machine learning**

268 The fitted ML models were applied to out-of-sample Ct data from the simulated Ct values

269 (**Figure 3**). With increasing sample sizes, the MSE across each model reduced by 82% showing

270 an increased ability in higher moments (mean, median, variance, skewness and kurtosis) of the

271 Ct distribution to predict epidemic trends. Random Forest showed the largest improvement in

272 MSE performance while demonstrating lowest performance in smaller sample size. Besides the

273 smallest sample size, all models generally perform similarly across an increased sample size

274 (**Figure 3**). For the largest sample size, apart from Lasso all other models have a much tighter

275 IQR and smaller MSE median score (at around 0.03). Across all sample sizes, the variance of the

- 276 Ct distribution was the top ranking feature (**Supplemental Figure 5**).
- 277

278 **Second modeling approach: epidemic transmission models**

279 **SEIR**

280 The most precise results were observed with sampling from a total of five horizons. The model

281 posteriors indicated an incidence peak from December 27 2021 to January 1 2022, which

282 overlapped with the observed peak of reported cases in the province (**Figure 4**). Similarly, the

- 283 exponential growth phase coincided with the increase in reported cases from our cohort from
- 284 December 20 2021 to December 27 2021, and the decline of the incidence coincided with the
- 285 decline in cohort cases from January 1 2022 to January 5 2022. The posterior predictive Ct

286 distribution also closely matched the observed Ct distribution on each of the time horizons,

287 supporting accurate incidence projection independent of biases of testing guidance.

288 **Outbreak case study**

289 This outbreak occurred in a long-term care facility, and resulted in a total of 156 individuals (93

290 residents and 63 staff) infected with SARS-CoV-2 (**Supplemental Figure 4**). Of these

291 individuals, 58.1% of infections were asymptomatic in the residents, whereas 9.5% were

292 asymptomatic within the staff. There were 26 (28.0%) deaths in the residents group, and no

293 deaths among the staff. A multiple cross-section SEIR model was fitted to the outbreak data, and

294 showed a peak in incidence on the 12th day of the outbreak which preceded by two days the

295 observed peak at the outbreak facility (**Figure 5**). The real incidence fell within the 95% credible

296 interval of the predicted MCMC chains of the SEIR model. The model also accurately predicted

297 the decline in cases by the 20th day of the outbreak (**Figure 5**).

298

299 *Discussion*

300 In this study, we demonstrated the utility of two distinct modeling approaches based on 301 aggregated cycle threshold values, machine learning and epidemic transmission modeling, to 302 predict epidemic trends across varying sampled patient populations, random, and targeted and 303 non-random testing. Based on out-of-sample mean squared error (MSE) change in the 304 reproduction number between the true and predicted values, the ML model performed best on 305 randomly-sampled province-level data. Within epidemic transmission models, the SEIR model 306 performed highest with randomly-sampled outbreak data. Taken together, these approaches 307 accurately predicted epidemic transmission dynamics at the outbreak case study level, and at a 308 provincial level for the province of BC, Canada. Early in the pandemic, SARS-CoV-2 diagnostic

309 molecular testing was more largely based on random sampling which, despite possible 310 underascertainment due to lack in testing access, could be used to estimate full case counts to 311 monitor and predict transmission dynamics. As testing needs overwhelmed laboratory capacity 312 with increasing case burden and the emergence of variants of concern, molecular testing practice 313 recommendations shifted to testing individuals who were symptomatic and/or with a minimal 314 illness severity, resulting in sampling of a selected population. These changes in testing 315 indications, foremost predicated on symptom-based testing, led to substantially more limited 316 capacity to assess case counts for epidemic monitoring, generating a critical unmet need for other 317 approaches to infer epidemic trends to support clinical and public health planning. 318 319 This study comprehensively investigated varying sampling types and modeling approaches, 320 drawing on both previously-published work and description of the novel application of machine 321 learning modeling for SARS-CoV-2 transmission dynamics prediction. Our work identified that 322 diagnostic testing indication, sampling type, and the individual population tested are critical 323 factors, and that model selection must be tailored to the epidemiological circumstances of 324 testing. More specifically, random vs targeted or non-random sampling must be accounted for to 325 ensure appropriate model selection, as SEIR modeling was only suitable for random sampling. 326 For example, performance of the SEIR model in this study was robust across sample sizes and 327 the long-term care facility dataset. Results from this modeling approach demonstrated a slight 328 difference in incidence peak timing and amplitude. This is likely explained due to the lag time 329 between onset of the infectious period and reporting given that site-wide facility testing was 330 performed at set time periods rather than on a daily basis, and represents a pragmatic approach to 331 real-world settings. Thus, this approach is well suited for long-term care or assisted living or

332 community-living facility outbreak investigations such as shelters, or within small hospital 333 systems. In contrast, the novel application of machine learning approaches described in this 334 study performed the best with large datasets (>1,000 COVID-19 positive cases), making this the 335 approach of choice for large population settings such as at the province, state or large hospital 336 network system level. Indeed, machine learning models can offer greater flexibility by 337 incorporating different summary statistics and other data as features, fully harnessing the 338 potential of larger datasets.

339

340 Importantly, all approaches described in this study could predict future trends within a one to 341 four-week timeframe, demonstrating utility for timely prediction of SARS-CoV-2 transmission 342 dynamics that could be harnessed to help inform future outbreak resource allocation and 343 decision-making. Thus, use of these models can be used to support critical decision-making 344 across several settings, including hospitals, long-term care facilities, public health departments 345 and others, to help inform planning of resource allocation, vaccination efforts, and isolation 346 practices. More specifically, this approach lays the groundwork for a sentinel surveillance 347 monitoring strategy that could be automated and alert appropriate authorities at pre-determined 348 signals of predicted incidence changes, and may be expanded to other infections for which 349 testing is widespread and predictive tools are needed.

350

351 This study focused on a time period of Omicron (BA.1) predominance, and revealed that despite 352 its shorter incubation period compared to other variants of concern, the Ct distribution of this 353 variant could successfully be described through an SEIR compartmental model and machine 354 learning approaches. Furthermore, in the context of a sampled population with heterogeneous

355 vaccination status, the current study demonstrated accurate prediction of incidence based on 356 overall Ct distribution and viral kinetics without incorporating individual-level vaccination 357 status. Further work is necessary to study the impact of vaccination status on accuracy of 358 incidence prediction.

359

360 The main strength of this study is that it provides a comprehensive modeling toolkit that can be 361 leveraged across population and sampling settings, and that may incorporate covariates such as 362 variant of concern and vaccination status. This approach could predict transmission dynamics in 363 a way that could not be performed through case count analysis from biased sampling as was 364 occurring in the province of BC. This modeling is also advantageous as it can be performed in 365 real-time, rather than rely on monitoring of clinical indicators of severity such as hospitalization 366 and intensive care unit admission which considerably lag behind true incidence rise. A limitation 367 of previous studies is the use of a single or limited methodology for analysis that may perform 368 well in a specific setting such as long-term care facilities, but lacked flexibility and predictive 369 performance for generalizability to larger settings and in the context of changing testing practices 370 (3). Our body of work filled this gap and further presented a methodology to incorporate 371 assessment of variant of concern and vaccination status, two important potential confounders on 372 Ct value distribution, although these characteristics were noted to be less important than the 373 moments of infection (mean, median, variance, skewness and kurtosis of the aggregated Ct 374 distribution). Additional strengths of this study also include the independent assessment of the 375 models in a long-term care facility outbreak to validate the previously-published models (3). 376 Furthermore, the main analysis drew on a provincial dataset linking laboratory data and 377 vaccination status in real-time, thus leveraging the design for the highest possible public health

378 uptake and impact. Taken together, this approach lays the framework for expansion to use for 379 other pathogens for which surveillance needs are critical including other respiratory pathogens 380 and monkeypox. Indeed, further work may also build on this approach and further integrate 381 complementary datasets including wastewater Ct distribution to further enhance prediction 382 ability.

383

384 However, there are several limitations. Firstly, the methodology is based on the assumption of 385 random or random sampling which is challenging to confirm. Indeed, testing practices were 386 modified following clinical and public health guidance of the province, and may have led to bias 387 in sampling. Restriction of the study population to the asymptomatic subgroup consisting of 388 travelers and occupational health testing led to greater confidence in the employed sampling 389 strategy tested and the validity of this assumption. The need for random sampling remains a 390 limitation for broader uptake of this approach, though it may be more attainable in the context of 391 outbreak investigation where full populations are sampled at once. Nonetheless, even when a full 392 population is sampled there may be specific population-level characteristics that need to be 393 accounted for. One such limitation in the current work is that although the long-term care 394 environment provides more a consistent testing environment, it tends to be a highly vaccinated 395 population which may introduce bias. Finally, this study aggregated Ct-level data across multiple 396 laboratories and assays, which may not adequately capture intra- and inter-assay variation. 397

398 In summary, this study proposes a comprehensive suite of modeling strategies based on 399 population-level Ct values to accurately predict SARS-CoV-2 transmission dynamics across 400 epidemiological settings. These modeling approaches can be used in real time to guide clinical

401 and public health interventions. Such tools are needed to estimate incidence in a manner that is 402 independent of the biases associated with testing guidance, and to complement traditional 403 surveillance based on case numbers or clinical indicators. Further work will be needed to expand 404 validation of the machine learning models based on larger datasets and different settings with 405 newly-emerging variants, to assess real-time predictive power for direct clinical and public 406 health impact. 407 408 409 **Funding:** This work was supported by funding by Genome BC, Michael Smith Foundation for 410 Health Research and British Columbia Centre for Disease Control Foundation to C.A.H. This 411 work was also funded by the Public Health Agency of Canada *COVID-19 Immunity Task Force* 412 *COVID-19 Hot Spots Competition Grant (2021-HQ-000120)* to M.G.R. 413 **Acknowledgments:** We thank the laboratory teams (virology, bacteriology and molecular) at the 414 BCCDC Public Health Laboratory for their contribution toward testing, on which this research is 415 based. We also thank the data analytics team for supporting the data infrastructure and review 416 that enabled this work. Finally, we thank the British Columbia Association of Medical 417 Microbiologists for testing and sharing samples and data that enabled province-wide data 418 collection, and public health partners throughout the province for their dedicated effort to 419 outbreak management and infection control, and for sharing outbreak-level data that supported 420 this research.

466 **doi:10.1093/cid/ciab**/21.

- 512 24. Tibshirani R. 1996. Regression shrinkage and selection via the Lasso. Journal of the
- 513 Royal Statistical Society Series B (Methodological) 58:267-88.
- 514 25. Lundberg S. LS. 2017. A unified approach to interpreting model predictions, abstr 31st 515 Conference on Neural Information Processing Systems (NIPS 2017),

- 517 **Table 1.** Epidemiological, clinical and laboratory data of the cohort of asymptomatic individuals
- 518 tested during the test period of the study.
- 519

 520 *For all group variables except testing, data presented as first positive result per person 521 **Does not include individuals who received ≥ 3 doses of vaccine

**Does not include individuals who received \geq 3 doses of vaccine

522

523 NP: nasopharyngeal; SG: saline gargle; VoC: variant of concern

525

526 * Relative computational complexity based on assumed sample size provided in scalability row

527 COVID-19: coronavirus disease 2019; SEIR: susceptible-exposed-infected-recovered; ML:

528 machine learning; Ct: cycle threshold

530 A.

531

534

535

- 536 **Figure 1.** Overall design (A) and flowchart (B) of the study.
- 537 BC: British Columbia; E gene: Envelope gene; SARS-CoV-2: Nov: November; Rt: reproductive
- 538 number; SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2

Ct in the province in Phase 3

540 A.

543

544 **Figure 2.** Violin plots demonstrating the cycle threshold value distribution (A) and absolute

545 number of cases of confirmed SARS-CoV-2 infection (B) in British Columbia across different

546 time points of the study period.

547 Ct. e: Envelope (*E*) gene cycle threshold value; SARS-CoV-2: SARS-CoV-2: severe acute

548 respiratory syndrome coronavirus type 2

551

552 **Figure 3**. Boxplot representation of MSE scores across models on out-of-sample simulated cycle 553 threshold data.

- 554 LGBM: Light Gradient Boosting Model; MSE: Mean squared error; XGBM: eXtreme Gradient
- 555 Boosting Model, ML: Machine Learning

557

558

559 **Figure 4.** Overall population modeling findings. A multiple-cross section SEIR model was fitted 560 to the overall population-level data (I), and showed an incidence peak from December 27 2021 to 561 January 1 2022, which overlapped with the observed peak of reported cases in the province. The 562 Monte Carlo chain model-predicted incidence curve is represented (black lines), and was 563 overlaid with the reported number of confirmed SARS-CoV-2-positive (yellow bars) cases. 564 Violin plots of the viral kinetic parameters for the SEIR model are presented (II). Three unique 565 time horizons were chosen, each of which is depicted by a different color. The MCMC approach 566 searches over the viral kinetic parameters presented above, and is based on prior values 567 described separately (**Supplemental Table 6**). To align with the described Omicron viral 568 kinetics, the incubation period was fixed and set at three days, and the infectious viral kinetic

- 569 parameter was fixed. An upper bound of I_0 was set at 0.100. The fit to detectable cycle threshold
- 570 distribution and the fit to proportion variable are presented over different time points (A).
- 571
- 572 Ct: cycle threshold; SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2; SEIR:
- 573 susceptible-exposed-infected-recovered

prob detec

 $t0$

 100

 150

 0.20

 0.15

 0.05

 1.0

 0.5

 0.0

 0.5

 -1.0

 $\frac{9}{2}$ _{0.10}

 $\mathsf{R}0$

viral peak

100 sampno

 $10.0¹$ 9.5

 9.0

 $8.5 8.0 -$

 7.6

 $17[°]$

 $16¹$ $15₁₅$

 $14 -$

 13 12

 200

t_switch

575 Figure 5. Long-term care facility outbreak investigation modeling findings. a multiple-cross 576 section SEIR model was fitted to the outbreak data (I), and showed a peak in incidence on the

- 577 12th day of the outbreak which preceded by two days the observed peak at the outbreak facility.
- 578 The population included in this outbreak investigation was sampled at three pre-determined time
- 579 points (dashed red lines). The Monte Carlo chain model-predicted incidence curve is represented
- 580 by black lines, and was overlaid with the reported number of confirmed SARS-CoV-2-positive
- 581 cases in this outbreak setting (yellow bars). Violin plots of the viral kinetic parameters for the
- 582 SEIR model are also presented in the outbreak case study (II).
- 583
- 584 Ct: cycle threshold; SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2; SEIR:
- 585 susceptible-exposed-infected-recovered
- 586

588 *The current study included Phase 3 only

589 **Vaccination phases were defined by vaccine eligibility of the target populations in BC, and are

590 detailed separately (21)

591
592 SARS-CoV-2: SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2

- 593 **Supplemental Table 2.** SARS-CoV-2 diagnostic testing strategy based on the envelope (*E*) gene target and test result interpretation
- 594 criteria used for the participating laboratories

595

596 BCCDC PHL: British Columbia Centre for Disease Control Public Health Laboratory; Ct: cycle threshold; FHA: Fraser Health

597 Authority; IHA: Interior Health Authority; LDT: laboratory-developed test; NHA: Northern Health Authority; PCR: polymerase chain

598 reaction; SARS-CoV-2: severe acute respiratory syndrome coronavirus type 2; SPH: St. Paul's Hospital; VCH: Vancouver Coastal

599 Health.

600 **Supplemental Table 3.** Epidemiological, clinical and laboratory data of the earlier British Columbia SARS-CoV-2 pandemic phases

601

VoC: variant of concern

603 **Supplemental Table 5.** Hyperparameter selection

604

606 Boosting Model

⁶⁰⁵ RF: Random Forest; LGBM: Light Gradient Boosting Model; XGBM: eXtreme Gradient

608 **Supplemental Table 6.** Control table of priors for SEIR model

609 *Adapted parameters (3)

610

611 SEIR: susceptible-exposed-infected-recovered

616 for saline gargle compared to nasopharyngeal specimens for the entire study period.

617 Ct. e: Envelope (*E*) gene cycle threshold value; NP: nasopharyngeal

618

619

621

623 **Supplemental Figure 2.** Twenty most prevalent SARS-CoV-2 variant of concern lineages in

- 624 British Columbia from January 2021 to January 2022. The current study was performed during a
- 625 time of Omicron variant predominance, from November19 2021 to January 8 2022.
- 626 BCCDC: British Columbia Centre for Disease Control; SARS-CoV-2: severe acute respiratory
- 627 syndrome coronavirus type 2

628

630

631 **Supplemental Figure 3.** Vaccination status definitions. Vaccination status was defined based on 632 the date of vaccine receipt relative to the date of the sample collection included for the study. For 633 the Janssen vaccine only, fully vaccinated status was defined as having received one dose 14 634 days or more prior to sample collection. For all other vaccines, **Unvaccinated status** was defined 635 as having received no SARS-CoV-2 vaccine, or having received a SARS-CoV-2 vaccine less 636 than 21 days prior to the sample collection date. **Partially vaccinated** status was defined as 637 having received the SARS-CoV-2 vaccine dose 1 greater or equal to 21 days prior to sample 638 collection, but having received dose 2 less than 14 days prior to the sample collection. **Fully** 639 **vaccinated** status was defined as greater or equal to 14 days since the receipt of dose 2, but 640 having received dose 3 less than 14 days prior to the sample collection. 641

644 A.

645

646 B.

647

648 **Supplemental Figure 4.** Case study epidemiological data (A) and epidemic curve (B) for the 649 156 infected individuals in the long term care facility outbreak.

651

652 **Supplemental Figure 5.** SHAP summary outputs explaining the machine learning output based 653 on simulated cycle threshold (Ct) data. Results are presented stratified by three different

654 population sizes: 100, 1,000 and 10,000 with each column in descending order of performance.

- 655 Of the five features explored, the top ranking feature across all models was the variance of the Ct
- 656 data.
- 657 SHAP: SHapley Additive exPlanations; LGBM: Light Gradient Boosting Model; XGBM:
- 658 eXtreme Gradient Boosting Model

659